Evidence map›Paper›PMID 33907226›Full record

ArticleScientific reports2021

Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE

Pontus Dunér, Ingrid Yao Mattisson, Per Fogelstrand, Lars Glise, Stacey Ruiz, Christopher Farina, Jan Borén, Jan Nilsson, Eva Bengtsson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Mitigating atherosclerosis: Integrating vaccines with gene targets.American heart journal plus : cardiology research and practice · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.International journal of molecular sciences · 2021
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Pontus DunérDepartment of Clinical Sciences Malmö, Clinical Research Centre, Lund University, Jan Waldenströms street 35, 20502, Malmö, Sweden. pontus.duner@med.lu.se.
Ingrid Yao MattissonDepartment of Clinical Sciences Malmö, Clinical Research Centre, Lund University, Jan Waldenströms street 35, 20502, Malmö, Sweden.
Per FogelstrandDepartment of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Göteborg, Sweden.
Lars GliseDepartment of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Göteborg, Sweden.
Stacey RuizAbcentra LLC, Los Angeles, CA, USA.
Christopher FarinaAbcentra LLC, Los Angeles, CA, USA.
Jan BorénDepartment of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Göteborg, Sweden.
Jan NilssonDepartment of Clinical Sciences Malmö, Clinical Research Centre, Lund University, Jan Waldenströms street 35, 20502, Malmö, Sweden.
Eva BengtssonDepartment of Clinical Sciences Malmö, Clinical Research Centre, Lund University, Jan Waldenströms street 35, 20502, Malmö, Sweden.
Lund University · SEAbcentra (United States) · USUniversity of Gothenburg · SERedoxis (Sweden) · SESahlgrenska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerotic plaques are characterized by an accumulation and subsequent oxidation of LDL, resulting in adaptive immune responses against formed or exposed neoepitopes of the LDL particle. Autoantibodies against native p210, the 3136-3155 amino acid sequence of the LDL protein apolipoprotein B-100 (apoB100) are common in humans and have been associated with less severe atherosclerosis and decreased risk for cardiovascular events in clinical studies. However, whether apoB100 native p210 autoantibodies play a functional role in atherosclerosis is not known. In the present study we immunized apoE

Indexed as

AnimalsApolipoprotein B-100AtherosclerosisAutoantibodiesFemaleFusion Proteins, bcr-ablImmunoglobulin GLipoproteins, LDLMalaria VaccinesMalondialdehydeMicePeptide FragmentsApob protein, mouseApolipoprotein B-100AutoantibodiesFusion Proteins, bcr-ablImmunoglobulin GLipoproteins, LDLMalaria VaccinesMalondialdehydemalondialdehyde-low density lipoprotein, mousePADRE 45Peptide Fragments

Identifiers

PMID33907226
PMCPMC8079692
OpenAlexW3159024532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.